Where are you?
To give you the most accurate information about our products and what we can do for you, we need to direct you to the right site.
To give you the most accurate information about our products and what we can do for you, we need to direct you to the right site.
Extraordinary General Meeting of Kuros Biosciences approves all resolutions
Kuros announces the terms of the proposed capital increase through a discounted rights offering expected to raise up to CHF 12 million gross proceeds for the commercialization of its products and the further development of its product candidates
Kuros convenes Extraordinary General Meeting
Kuros Biosciences to Host Key Opinion Leader Meeting in Zurich Showcasing its Commercial Stage Advanced Bone Graft MagnetOs
Kuros Biosciences announces full commercial launch of MagnetOs™ and exhibitor status at North American Spine Society 34 th Annual Meeting
Kuros Biosciences Announces U.S. FDA approval of IND Application to Initiate Fibrin-PTH Phase 2a Clinical Trial in Spinal Fusion